Badan Penyelenggara Jaminan Sosial-Kesehatan [Indonesian Social Security Agency for Health]. Penderita skizofrenia bisa mendapat pelayanan Kesehatan melalui JKN-KIS [Patients with Schizophrenia can Access Healthcare Provison through National Insurance], 2017. Available via https://bpjs-kesehatan.go.id (Accessed 27 March 2020). |
|
Badan Penyelenggara Jaminan Sosial-Kesehatan [Indonesian Social Security Agency for Health]. Gangguan Kejiwaan Dijamin BPJS Kesehatan, 2022. Available via https://bpjs-kesehatan.go.id/bpjs/post/ read/2022/2161/Gangguan-Kejiwaan-Dijamin-BPJS-Kesehatan (Accessed 28 February 2022). |
|
Beasley CM, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol, 2003; 23:582-94. https://doi.org/10.1097/01.jcp.0000095348.32154.ec |
|
Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs, 2001; 61:111-61. https://doi.org/10.2165/00003495-200161010-00011 |
|
Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat, 2016; 12:357-73. https://doi.org/10.2147/NDT.S96649 |
|
Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz-Carrasco P, Anton-Saiz C, Fontova-Carbonell E. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry, 2000; 61:335-43. https://doi.org/10.4088/JCP.v61n0503 |
|
Grunder G, Heize M, Cordes J, Muhlbauer B, Juckel G, Schulz C, Ruther E, Timm J. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry, 2016; 3:717-29. https://doi.org/10.1016/S2215-0366(16)00085-7 |
|
Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics, 1999; 15:469-80. https://doi.org/10.2165/00019053-199915050-00005 |
|
Hayhurst KP, Massie JA, Dunn G, Lewis SW, Drake RJ. Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatry, 2014; 14:365. https://doi.org/10.1186/s12888-014-0365-x |
|
Indonesian Ministry of Health. Report of Basic Health Research, 2018. Available via http://labmandat.litbang.depkes.go.id/images/ download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf (Accessed 1 April 2020). |
|
Institution of Health Metrics and Evaluation. Global health data exchange, 2019. Available via http://ghdx.healthdata.org/gbd-resultstool?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589 dd7 (Accessed 25 September 2021). |
|
Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics, 2017; 35:25-42. https://doi.org/10.1007/s40273-016-0444-6 |
|
Kementerian Kesehatan Republik Indonesia [Indonesian Ministry of Health]. Pedoman Nasional Pelayanan Kedokteran Jiwa [National Guideline on Psychiatric Disease Management]. Kementerian Kesehatan Republik Indonesia, [Indonesian Ministry of Health], Jakarta, Indonesia, 2015. |
|
Krejcie RV, Morgan DW. Determining sample size for research activities. Educ Psychol Measure, 1970; 30:607-10. https://doi.org/10.1177/001316447003000308 |
|
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009; 373:31-41. https://doi.org/10.1016/S0140-6736(08)61764-X |
|
Montoya A, Valladares A, Lizan L, San L, Escobar R, Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes, 2011; 9:18. https://doi.org/10.1186/1477-7525-9-18 |
|
Muhareni D, Aanggriani Y, Purba FD. Analisis Efektivitas Biaya Terapi Olanzapin dan Kombinasi Haloperidol dengan Diazepam secara Intramuskular pada Pasien Rawat Inap Skizofrenia Fase Akut di RSKD Duren Sawit [Cost effective Analysis of Intramuscular Olanzapine and Combination of Intramuscular Haloperidol with Diazepam in Acute Phase Schizophrenia Inpatients in Duren Sawit Psychiatric Hospital]. Majalah Farmasi dan Farmakologi, 2021; 25:28-31. |
|
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management, 2014. Available via https://www.nice.org.uk/guidance/cg178/resources/ psychosis-and-schizophrenia-in-adults-prevention-and-managementpdf-35109758952133 (Accessed 16 July 2019). |
|
Pinem VE. Perbandingan Olanzapin Intramuskular dan Haloperidol Intramuskular dalam penanganan Agitasi pada Pasien Skizofrenik [Comparison of Intramuscular Olanzapin and Intramuscular Haloperidol In Management of Agitation in Schizophrenia]. Postgraduate Thesis, University of North Sumatra, 2010. |
|
Purba FD, Hunfeld JAM, Iskandarsyah A, Fitriana TS, Sadarjoen SS, Ramos-Goni JM, Passchier J, Busschbach JJV. The Indonesian EQ-5D5L Value Set. PharmacoEconomics, 2017; 35:1153-65. https://doi.org/10.1007/s40273-017-0538-9 |
|
Rascati KL. Essentials of pharmacoeconomics. Lippincott Williams & Wilkins, Philadelphia, PA, 2009. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatr, 2017; 62:604-16. https://doi.org/10.1177/0706743717720448 |
|
Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease-a nonsystematic review of epidemiology, possible causes, and interventions. Front Psychiatr, 2014; 5:137. https://doi.org/10.3389/fpsyt.2014.00137 |
|
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: a randomized controlled trial. JAMA, 2003; 290:2693-702. https://doi.org/10.1001/jama.290.20.2693 |
|
Sacristan JA, Gomez JC, Montejo AL, Vieta E, Gregor KJ. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. Clin Ther, 2000; 22:583-99. https://doi.org/10.1016/S0149-2918(00)80046-6 |
|
The American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2020. Available via https:// psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841. https://doi.org/10.1176/appi.books.9780890424841 |
|
Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry, 1997; 154:457-65. https://doi.org/10.1176/ajp.154.4.457 |
|
Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry, 1999; 60(Suppl 19):38-45; discussion 46. |
|
Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatr, 7:58-62. https://doi.org/10.1002/j.2051-5545.2008.tb00154.x |
|
Vos T, Barber R, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhards L, Dicker D, Duan L, Erskine H, Feigin V, Ferrari A, Fitzmaurice C, Fleming T, Graetz N, Guinovart C, Haagsma J, Yadav A. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015; 386:743-800. https://doi.org/10.1016/S0140-6736(15)60692-4 |
|
Wei Xin Chong J, Hsien-Jie ET, Chong CE, Ny Y, Wijesinghe R. Atypical antipsychotics: a review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. Ment Health Clin, 2016; 6:178-84. https://doi.org/10.9740/mhc.2016.07.178 |
|
World Health Organization. Mental disorders, 2018. Available via https://www.who.int/news-room/fact-sheets/detail/mental-disorders (Accessed 29 June 2020). |
|
Zhang G, Sackman RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol, 2015; 6:225. https://doi.org/10.3389/fphar.2015.00225 |